Nova StatStrip Glucose Meter FDA Update: What the Gen 2.0 Software Issue Means for Hospitals and the Maker
The Nova StatStrip glucose meter FDA update could pull Gen 2.0 meters from wards. Operational impact, commercial exposure and open questions.
Nova StatStrip Glucose Meter FDA Update: What the Gen 2.0 Software Issue Means for Hospitals and the Maker
The Nova StatStrip glucose meter FDA update could pull Gen 2.0 meters from wards. Operational impact, commercial exposure and open questions.
HemosIL AcuStar Recall: What the FDA Class I Action Means for Werfen, Labs and Diagnostics Supply
The HemosIL AcuStar recall puts Werfen under a Class I FDA action. Supply disruption, customer trust and what is still unknown.
Narayana Health Q2 Results FY27: Revenue Up 73%, but Organic Growth Is 22.6% as UK Deal Dilutes Margins
The Narayana Health Q2 results FY27: 73% revenue growth, 22.6% without the UK. A business look at margins, finance costs and what to watch.
Rainbow Children’s Medicare Q2 FY27 Results: Revenue Up 23% as Expansion Squeezes Margins
The Rainbow Children Q2 FY27 results: revenue up 23%, profit up 11%. A business look at expansion costs, margins and what comes next.
Assam Proton Therapy Centre: Financing, Utilisation and Execution Risks of a ₹600 Crore Public Project
The Assam proton therapy centre is a ₹600 crore public bet. Financing split, utilisation questions and execution risks.
INOVIO VOCERYQ FDA Approval: Launch Plan, Competition and the Commercial Risks of Accelerated Approval
The INOVIO VOCERYQ FDA approval starts a launch in about 60 days. Competition, accelerated-approval risk and undisclosed price.
India Pharmaceutical Market Growth 2026: Who Is Capturing the 12% Rise to ₹70,180 Crore
Who captures India pharmaceutical market growth 2026? Sun, Torrent and Mankind outgrew the 12% market. Pricing and caveats.
Bristol Myers Squibb Q3 2026 Results: Growth Portfolio Now 59% of Sales as Eliquis Cliff Nears
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as the Growth Portfolio hits 59% of sales. The Eliquis cliff explained.
Laurus Labs Galenvs Acquisition: A Small Ticket Aimed at Oligonucleotide Capability
The Laurus Labs Galenvs acquisition is a US$3.75 million option on oligonucleotide skills. Deal math, strategy and risks.
